This week’s picks cover: Why ADUS HomeCare is a high quality name with defensive revenues worth watching, why near term skepticism on Verve Group may be overdone, and how Grab's network effects could allow it to dominate South East Asia as a super-app.
SPDR Gold Trust (GLD) is in focus after gold prices hit new all-time highs in 2025, with inflation and geopolitical worries drawing eyes to the yellow metal. Recent headlines highlight how gold-backed ETFs are becoming top choices for investors seeking secure, liquid access to bullion during times of uncertainty. For those considering whether to take action, GLD’s prominent liquidity and direct exposure to gold make it a leading name in this space.
Amid this gold rally, SPDR Gold Trust has...
If you have been eyeing Smart Digital Group (NasdaqCM:SDM), this week’s flurry of activity may be the nudge you were waiting for. The company’s recent Nasdaq debut caught plenty of attention, but what is keeping the momentum alive is a mix of robust early revenue numbers and ongoing buzz over its plans for an AI-driven marketing platform. With investors watching the Asia-Pacific digital ad market heat up, SDM’s drive to expand in the region and its fresh injection of capital are setting the...
If you’ve been tracking Black Rock Coffee Bar (BRCB), you might have noticed the company quietly inching past headlines lately. While there hasn't been a single seismic event to jolt investors, the recent trading patterns have turned some heads. On the surface, the moves are subtle, with no bombshell announcements or abrupt surges. Still, even small shifts can spark bigger questions about where the value lies and what the market is forecasting for this growing player in the coffee...
Biogen recently announced that the U.S. FDA accepted its investigational new drug application for BIIB142, an IRAK4 degrader developed in collaboration with C4 Therapeutics, for the treatment of autoimmune diseases.
This regulatory milestone highlights C4 Therapeutics’ expertise in targeted protein degradation and the momentum in its partnerships, which are advancing clinical-stage candidates.
We'll explore how Biogen's progress with BIIB142 influences C4 Therapeutics' investment narrative...
